Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood thinner is safer? major trial pits rivaroxaban against apixaban

NCT ID NCT04642430

Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two blood thinners, rivaroxaban and apixaban, to see which causes less bleeding in people with atrial fibrillation (an irregular heartbeat). About 3,000 adults who need to start blood thinners will take one of the two drugs. The goal is to find which medication offers the best balance of stroke prevention and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 3,018 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines Exclusion Criteria: * Creatinine clearance =\<15 ml/min calculated using the Cockcroft-Gault formula * Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to: * active bleeding * history of mechanical valve * other indication for anticoagulation (e.g. mechanical valves, venous thrombosis) * dual antiplatelet agent use * known liver disease with coagulopathy * use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein) * pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Quebec - Université Laval

    NOT_YET_RECRUITING

    Laval, Quebec, Canada

  • CISSS de l'Outaouais

    RECRUITING

    Gatineau, Quebec, J8T 4J3, Canada

  • Ciusss Nim

    RECRUITING

    Montreal, Quebec, H3L 1K5, Canada

  • Kingston General Hospital

    RECRUITING

    Kingston, Ontario, Canada

  • QEII Health Science Centre

    RECRUITING

    Halifax, Nova Scotia, Canada

  • The Ottawa Hospital - General Campus

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • University Ottawa Heart Institute

    RECRUITING

    Ottawa, Ontario, Canada

  • Victoria Cardiac Arrhythmia Trials

    RECRUITING

    Victoria, British Columbia, V8Z 0B9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.